BI 201335 enters Phase III for Hepatitis C

Boehringer Ingelheim announced that enrollment has commenced at North American sites in its pivotal Phase III clinical trial program for BI 201335, the Company's investigational, oral protease inhibitor for the treatment of chronic hepatitis C virus (HCV). Phase III trials have begun recruiting to evaluate BI 201335 plus standard-of-care (SOC) in both treatment-naive and -experienced patients with chronic genotype-1 HCV, the most challenging HCV genotype to treat. Results from the Phase III studies are expected in the first half of 2013.